Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Sep;14(3):3207-3214.
doi: 10.3892/ol.2017.6477. Epub 2017 Jun 23.

Expression of miR-146a in patients with ovarian cancer and its clinical significance

Miłosz Wilczyński  1 , Ewelina Żytko  2 , Bożena Szymańska  3 , Monika Dzieniecka  4 , Marek Nowak  2 , Justyna Danielska  5 , Grzegorz Stachowiak  2 , Jacek R Wilczyński  2
Affiliations

Expression of miR-146a in patients with ovarian cancer and its clinical significance

Miłosz Wilczyński et al. Oncol Lett. 2017 Sep.

Abstract

The aim of the present retrospective study was to compare microRNA (miR)-146a expression levels in primary tumors and omental metastases of 48 patients, who had undergone surgery for advanced ovarian serous cancer. Possible correlations between miR-146a expression level and clinicopathological features were investigated, including chemosensitivity and survival. miR-146a was evaluated in formalin-fixed, paraffin-embedded samples. miR-146a expression level in primary tumors was demonstrated to be increased in comparison with normal ovary tissues (P=0.02) and metastases (P=0.01). A negative correlation was demonstrated between miR-146a expression in primary tumors and serum levels of cancer antigen 125 (R=-0.37; P=0.03) and Risk of Malignancy Algorithm index (R=-0.79; P=0.0007). Overall survival positively correlated with miR-146a expression in primary tumor tissue samples (R=0.38; P=0.01). Probability of survival was decreased in patients with low miR-146a expression levels in primary tumor tissues (hazard ratio=0.21; P=0.003). Lower levels of miR-146a in primary tumor tissue samples were correlated with a shorter progression-free survival (P=0.04) and platinum-resistance of metastases (P=0.006). In conclusion, miR-146a may be a prognostic marker for serous ovarian cancer.

Keywords: cancer antigen 125; chemoresistance; microRNA-146a; ovarian cancer; risk of malignancy algorithm; survival.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
miR-146a expression level in primary tumor tissues and in normal ovarian tissues. P=0.02. miR, microRNA; RQ, relative quantification; SD, standard deviation.
Figure 2.
Figure 2.
miR-146a expression level in primary tumor tissues and in metastases (P=0.01). miR, microRNA; RQ, relative quantification; SD, standard deviation.
Figure 3.
Figure 3.
Correlation between miR-146a expression in primary tumor tissues and preoperative CA125 serum levels. P=0.03. miR, microRNA; RQ, relative quantification; CA125, cancer antigen 125.
Figure 4.
Figure 4.
Correlation between miR-146a expression in primary tumor tissues and preoperative ROMA index values. P=0.0007. miR, microRNA; RQ, relative quantification; ROMA, Risk of Malignancy Algorithm.
Figure 5.
Figure 5.
Correlation between miR-146a expression level in primary tumor tissues and overall survival (P=0.01). miR, microRNA.
Figure 6.
Figure 6.
Kaplan-Meier analysis of survival patients with ovarian cancer and miR-146a expression levels in primary tumor tissues. (P=0.003). OS, overall survival; miR, microRNA; RQ, relative quantification.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Trétarre B, Molinié F, Woronoff AS, Bossard N, Bessaoud F, Marrer E, Grosclaude P, Guizard AV, Delafosse P, Bara S, et al. Ovarian cancer in France: Trends in incidence, mortality and survival, 1980–2012. Gynecol Oncol. 2015;139:324–329. doi: 10.1016/j.ygyno.2015.09.013. - DOI - PubMed
    1. Edwards HM, Noer MC, Sperling CD, Nguyen-Nielsen M, Lundvall L, Christensen IJ, Høgdall C. Survival of ovarian cancer patients in Denmark: Results from the Danish gynaecological cancer group (DGCG) database, 1995–2012. Acta Oncol. 2016;55(Suppl 2):S36–S43. doi: 10.1080/0284186X.2016.1182641. - DOI - PubMed
    1. Cho KR, Shih IeM. Ovarian cancer. Annu Rev Pathol. 2009;4:287–313. doi: 10.1146/annurev.pathol.4.110807.092246. - DOI - PMC - PubMed
    1. Huang J, Hu W, Sood AK. Prognostic biomarkers in ovarian cancer. Cancer Biomark. 2010–2011;8:231–251. doi: 10.3233/CBM-2011-0212. - DOI - PMC - PubMed
    1. Lu LF, Boldin MP, Chaudhry A, Lin LL, Taganov KD, Hanada T, Yoshimura A, Baltimore D, Rudensky AY. Function of miR-146a in controlling Treg cell-mediated regulation of Th1 responses. Cell. 2010;142:914–929. doi: 10.1016/j.cell.2010.08.012. - DOI - PMC - PubMed